The Genetics Podcast
Sano Genetics
0
Dr Patrick Short, CEO of Sano Genetics and a University of Cambridge alumnus, explores the world of genetics. He dives into the science, interviews experts, and discusses the latest discoveries and advances in genetic research. The podcast also highlights the mission of Sano Genetics to accelerate the future of precision medicine. Listeners can learn more at the Sano Genetics website.
Episodes
-
EP 266: How patient communities are accelerating rare disease research with Tania Simoncelli of Biohub 19.11.2026 47mThis week on The Genetics Podcast, Patrick is joined by Tania Simoncelli, Vice President of Translational Impact and Engagement at Biohub. They discuss how patient-led organizations drive rare disease research, the capacity building and partnerships behind the Rare As One network, how AI could change drug repurposing and clinical trials, and Tania’s role in the ACLU case against human gene patents.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Tania01:41 The founding story and aim of the Rare As One Project05:17 Impact and scale of the Rare As One network, from funding to clinica... -
EP 265: How blood biomarkers are changing neurology diagnostics with Joe Volpe of Labcorp 12.11.2026 42mThis week on The Genetics Podcast, Patrick is joined by Dr. Joe Volpe, Executive Director, Scientific Strategy & Commercialization at Labcorp. They discuss how blood biomarkers like p-tau217 are changing Alzheimer’s diagnosis, which biomarkers are emerging in Parkinson’s disease and ALS, and what Labcorp’s real-world testing data reveals about how physicians use these tests.Show Notes0:00 Intro to The Genetics Podcast00:58 Welcome to Joe 01:47 Joe’s career in HIV genetics and his move into neurology06:35 Alzheimer’s blood biomarkers, beta amyloid, and the rise of p-tau21711:04 Why p-tau217 wor... -
EP 264: What AI’s math breakthroughs mean for drug development and genetics 05.11.2026 41mThis week on The Genetics Podcast, Patrick goes solo to look at what recent AI breakthroughs in mathematics could mean for biology. He discusses the OpenAI results on the Navier-Stokes equation and hundreds of open math problems, what makes math and code so easy for AI to improve on, how self-driving labs and surrogate endpoints could speed up drug development, and where the biggest gaps and opportunities remain.Show Notes0:00 Intro to The Genetics Podcast00:58 What the OpenAI math breakthroughs could mean for biology02:57 AI’s recent frontier math results and how mathematicians reacted09:12 L... -
EP 263: Bringing the first cardiovascular gene editing therapy to patients with Sek Kathiresan of Eli Lilly 29.10.2026 36mThis week on The Genetics Podcast, Patrick is joined by Dr. Sek Kathiresan, CEO of Verve Therapeutics and SVP, Head of Obesity Research and Early Development at Eli Lilly. They discuss how protective genetic variants led to the development of a one-time gene editing therapy for heart disease in the face of early doubt, the phase one results for Verve-102, what recent trial failures mean for genetic target validation, and the unmet needs in obesity treatment.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Sek 01:40 Sek’s family history of heart disease and how it motivated him to p... -
EP 262: The genetic drivers of hemochromatosis, drug response, and multimorbidity with Luke Pilling of the University of Exeter 22.10.2026 38mThis week on The Genetics Podcast, Patrick is joined by Dr. Luke Pilling, Senior Lecturer in Genetic Epidemiology at the University of Exeter. They discuss hemochromatosis and the case for earlier diagnosis, and the genetic drivers of multimorbidity, pharmacogenetics, and drug response.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Luke 01:37 An overview of HFE hemochromatosis and why diagnosis is delayed 04:24 Iron levels and overload risk in heterozygous and compound heterozygous carriers05:51 Aging-related effects seen in homozygotes 06:43 How hemochromatosis is currently diag... -
EP 261: Inside the virtual biotech staffed by AI agents with James Zou of Stanford University 15.10.2026 36mThis week on The Genetics Podcast, Patrick is joined by Dr. James Zou, Associate Professor of Biomedical Data Science at Stanford University. They discuss the concept of virtual biotechs and how AI agents link single cell data to clinical trial success, Paper to Agent and turning papers into living virtual authors, clinical AI from EchoNet to SleepFM, and the role of academia alongside big AI labs.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to James 01:55 An overview of James’s virtual biotech and its AI scientist agents04:11 How single cell evidence behind drug targets predicts... -
EP 260: How AI is reshaping genomics, disease prediction, and biosecurity with Jeffrey Barrett of the University of Helsinki 08.10.2026 45mThis week on The Genetics Podcast, Patrick is joined by Dr. Jeffrey Barrett, Group Leader at the Ellis Institute Finland and the University of Helsinki. They discuss using AI and federated biobank data to stratify common chronic diseases, how LLMs reading clinical notes in Finland's health registries can reveal treatment response, how AI is changing the way scientists research and train, and what the UK's COVID genome sequencing effort means for biosecurity.Show Notes0:00 Intro to The Genetics Podcast01:00 Welcome to Jeff 02:08 Jeff's research focus for his new lab, including molecular subtypi... -
EP 259: A patient community driving awareness and research for Danon disease with Jenny Hsieh of the Danon Foundation 01.10.2026 38mSummaryThis week on The Genetics Podcast, Patrick is joined by Jenny Hsieh, Co-Founder and President of the Danon Foundation. They discuss how Danon disease affects males and females, why it is so often misdiagnosed, the current therapy landscape and research priorities, and how families can make informed decisions about gene therapy trials.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Jenny 01:28 An overview of Danon disease02:34 Sex differences in Danon disease and severe disease in females05:15 Why Danon disease is misdiagnosed and how it may be spotted earlier08:50 Therapy p... -
EP 258: The mutations hiding in healthy tissues with Inigo Martincorena of the Wellcome Sanger Institute 24.09.2026 39mThis week on The Genetics Podcast, Patrick is joined by Dr. Inigo Martincorena, Group Leader at the Wellcome Sanger Institute. They discuss the discovery of widespread cancer-driver mutations in normal tissue, the role of somatic mutations in autoimmune disease, new sequencing technologies transforming the field, and the therapeutic potential of targeting these mutations.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Inigo 01:46 How Inigo's eyelid skin study revealed widespread cancer-driver mutations07:14 Findings from a follow-up study on esophageal tissue10:02 How NanoSeq tech... -
EP 257: Managing hereditary cancer risk and medical uncertainty with Marleah Dean Kruzel of the University of South Florida 17.09.2026 39mThis week on The Genetics Podcast, Patrick is joined by Dr. Marleah Dean Kruzel, Professor of Communication at the University of South Florida. They discuss her personal path from watching breast cancer move through her family to testing positive for a hereditary mutation herself, the ART framework she developed for managing uncertainty, and the complexities of communicating genetic risk within families.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Marleah01:35 Marleah's family history of breast cancer across four generations02:48 Marleah's childhood living through her mother's... -
EP 256: Cutting through the AI hype in drug discovery with Dave Hallett of Recursion 10.09.2026 40mThis week on The Genetics Podcast, Patrick is joined by Dr. David Hallett, Chief Scientific Officer at Recursion. They discuss the biggest shifts in drug discovery over Dave's three-decade career, where AI is genuinely transforming the field today versus where the hype outruns the reality, and how Recursion's perturbational maps have uncovered and validated a novel neurodegeneration target.Show Notes0:00 Intro to The Genetics Podcast01:00 Welcome to Dave01:57 The biggest shifts in drug discovery over three decades06:39 Where AI is delivering real wins across drug discovery today12:19 How AI-as... -
EP 255: Turning long-read sequencing into a routine part of clinical care with Danny Miller of the University of Washington 03.09.2026 36mThis week on The Genetics Podcast, Patrick is joined by Dr. Danny Miller, Assistant Professor of Pediatrics and of Laboratory Medicine and Pathology at the University of Washington and Attending Physician at Seattle Children's Hospital. They discuss the case for making long-read sequencing the first genetic test every patient receives, the reference dataset his lab is building from the 1000 Genomes Project to resolve structural variants, publicly available methylation signatures as biomarkers for diagnosis and treatment response, and his vision for genome-informed care from newborn screening t... -
EP 254: Triangulating genetic evidence and dodging bias to pick winning drug targets with Brent Richards of 5 Prime Sciences 27.08.2026 41mThis week on The Genetics Podcast, Patrick is joined by Dr. Brent Richards, CEO and Founder of 5 Prime Sciences and Professor of Human Genetics, Epidemiology, and Medicine at McGill University. They discuss how to triangulate different types of genetic evidence to validate a drug target, why herd psychology often drives which targets get funded, why strong genetic support didn't save the Zeus IL-6 trial, and how collider bias can distort genetically stratified clinical trials.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Brent01:43 How company size shapes access to genetic drug... -
EP 253: The genetics of brain size, growth, and aging with Andrew Jackson of the University of Edinburgh 20.08.2026 37mThis week on The Genetics Podcast, Patrick is joined by Dr. Andrew Jackson, Programme Leader at the MRC Human Genetics Unit at the University of Edinburgh. They discuss how his lab discovered that gain-of-function DNMT3A mutations cause both microcephalic dwarfism and an accelerated aging syndrome, and what that reveals about the shared biology of growth and aging.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Andrew01:34 The origins of Andrew's work linking brain size and aging02:54 The genetics of mammalian size range and epigenetic factors regulating growth05:02 How DNMT3A mut... -
EP 252: The diagnosis that became a mission to cure rare disease: Advancing genetic medicine using AI with Stevie Ringel of Nome 13.08.2026 37mThis week on The Genetics Podcast, Patrick is joined by Stevie Ringel, co-founder of Nome and founder of the Kizuna Foundation. They discuss Stevie's own ultra-rare disease diagnosis and shaped his path to founding Kizuna Foundation and Nome, how Nome's AI agents help scientists navigate the operational complexity of small-batch drug development, the technical and business model advantages underpinning Nome's accuracy, and what it will take to build a sustainable funding model for ultra-rare disease.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Stevie01:37 Stevie's inherited ret... -
EP 251: Cracking the delivery barrier in genetic medicine with Jagesh Shah of Mirai Bio 06.08.2026 38mThis week on The Genetics Podcast, Patrick is joined by Dr. Jagesh Shah, Chief Scientific Officer at Mirai Bio. They discuss why delivery is a central bottleneck holding back nucleic acid medicines, how Mirai's lipid nanoparticle (LNP) platform is built to reach tissues like adipocytes and T cells, and the machine learning feedback loop the company uses to engineer LNP formulations.Show Notes0:00 Intro to The Genetics Podcast01:00 Welcome to Jagesh01:40 Why delivery is the main bottleneck for gene therapies03:42 Easier vs harder tissues to target for delivery06:40 Overview of Mirai's modular d... -
EP 250: Redefining rare disease realities with Sharon Terry of the Genetic Alliance [Re-run] 30.07.2026 41mThis week on The Genetics Podcast, Patrick is joined by Sharon Terry, President & CEO of Genetic Alliance. They discuss how Sharon established a layperson-led biobank, her long-term work on rare diseases and patient advocacy, and her program to bring genetic technology to patients in low- to middle-income countries. We’re re-running this episode for its enduring lessons on patient advocacy, rare disease parenting, communication, and citizen science. Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Sharon and a discussion of the personal experience with rare disease that started her... -
EP 249: Building the world's most detailed genetic map of inflammatory bowel disease with Carl Anderson of the Wellcome Sanger Institute 23.07.2026 41mThis week on The Genetics Podcast, Patrick is joined by Dr. Carl Anderson, Senior Group Leader and Head of the Human Genetics Programme at the Wellcome Sanger Institute, where he leads the Genomics of Inflammation and Immunity Group. They discuss IBDVerse, the single-cell atlas Carl's team built to map genetic effects on gene regulation across gut cell types, how coding and non-coding variants converge on shared biological pathways in inflammatory bowel disease, and Carl's vision for longitudinal multi-omics cohorts built around the sickest and most underrepresented hospital patients.Show Note... -
EP 248: The blood mutations rewriting cardiovascular risk: Clonal hematopoiesis and polygenic risk with Pradeep Natarajan of Massachusetts General Hospital 16.07.2026 48mThis week on The Genetics Podcast, Patrick is joined by Dr. Pradeep Natarajan, Director of Preventive Cardiology at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. They discuss the discovery of clonal hematopoiesis as a driver of cardiovascular disease, the inflammatory mechanisms and emerging therapies targeting it, the growing clinical case for polygenic risk scores, and Pradeep's upcoming move to lead cardiometabolic and human genetics research at Amgen.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Pradeep01:30 The origin story of... -
EP 247: Why neurons accumulate mutations like clockwork: Somatic mosaicism and neurodegeneration with Christopher Walsh of Boston Children's Hospital 09.07.2026 37mThis week on The Genetics Podcast, Patrick is joined by Dr. Christopher Walsh, Professor of Pediatrics and Neurology at Harvard Medical School, Chief of Genetics and Genomics at Boston Children's Hospital, and HHMI Investigator. They discuss his path from neurobiology to human genetics, how somatic mosaicism in the brain drives disease from epilepsy to Alzheimer's, and what this reveals about new therapeutic targets for neurodegeneration.Show Notes0:00 Intro to The Genetics Podcast00:59 Welcome to Chris01:18 Chris’ path from neurobiology to human genetics04:55 How collaboration and mentorship...
Popular in
The podcast also appears in the podcast charts of these countries.